Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro's private drug price in the UK varies by dose and provider, and any legitimate cost includes a prescription issued after a clinical assessment — not just the pen itself. Since Eli Lilly raised UK list prices from September 2025, private market rates have typically ranged from around £149 to £375 per month depending on the dose, though quoted prices differ widely and don't always cover the same things. Mounjaro (tirzepatide) is a prescription-only medicine; a qualified prescriber must assess whether it is clinically appropriate for you before any treatment can be supplied.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro is tirzepatide, a dual GIP and GLP-1 receptor agonist made by Eli Lilly. Because it is a prescription-only medicine, its price in the private market is set by each provider independently. Eli Lilly increased its UK list price substantially from 1 September 2025 (the 15mg pen's list price rose from around £122 to roughly £330 per four-week supply) and that shift pushed private clinic and pharmacy prices upward across the board. As reported widely at the time, typical private rates now sit somewhere between £149 and £375 per month, varying by dose.
The doses currently licensed in the UK run from 2.5mg up to 15mg, titrated gradually by the prescriber as your treatment progresses. The 5mg pen sits in the middle of the starting range, and its private price tends to be lower than the higher maintenance doses. If you want a closer look, our breakdown of the mounjaro 5 mg price covers what you can expect to pay and why it varies between providers. You can also read more about why Mounjaro prices have risen and what drove that change. NICE's appraisal of tirzepatide (TA1026) is the clearest public reference for the eligibility criteria the UK clinical community uses.
A question our prescribers hear most weeks is: "I found it cheaper elsewhere, why is your price higher?" The honest answer is that headline prices vary because they don't always cover the same things. Some quotes are for the pen alone; others bundle in a consultation fee or prescription charge on top. Some providers charge separately for dose reviews, repeat prescriptions or clinical aftercare, meaning the monthly figure you see at the top of a price page is not always the figure you pay month after month.
Delivery charges are another common addition. A number of online services quote free first delivery and then apply a standard fee on repeats. For a medicine that requires ongoing clinical monitoring, those repeat costs add up. The full picture of Mounjaro pricing is worth reading before comparing quotes side by side. NHS England's guidance on weight-management injections also explains what a clinical pathway for these medicines involves, which is useful context for understanding why a consultation is part of the price, not optional overhead.
We are deliberately not the cheapest option on the market. That is not an apology, it is a deliberate decision about what kind of service we run. One transparent price at nume covers your free consultation, the prescription, the medicine itself, free next-working-day tracked DPD delivery and seven-day-a-week aftercare. There are no add-on fees, no subscription, and no auto-renewal. Every repeat order is clinically re-reviewed by a GPhC-registered Independent Prescriber before it is dispatched.
Identity is verified with photo ID. Weight is confirmed on a live video call before treatment begins. Where appropriate, our prescribers check Summary Care Records and, for patients transferring from another provider, ask for evidence of their current dose. That infrastructure costs something to run. The clinical team behind every consultation exists because Mounjaro is a prescription medicine, and prescription medicines require proper clinical oversight. You can see the full detail of how the service works on our about page.
The MHRA has repeatedly warned the public about counterfeit weight-loss pens circulating online and through social media, including fake tirzepatide pens. Large seizures of fake pens (in one case an illicit manufacturing site in Northampton was raided in October 2025) confirm that the supply of unlicensed versions of these medicines is not a theoretical risk. Sellers offering tirzepatide without a prescription, or advertising suspiciously low prices through social channels, are red flags the MHRA explicitly identifies. You can report suspect sellers at the MHRA's Yellow Card scheme.
For any prescription medicine, the right test is not the lowest price, it is whether the clinical assessment is real, the pharmacy is GPhC-registered and sourcing from the licensed UK supply chain, and the aftercare is there when you need it. You can verify any online pharmacy on the GPhC pharmacy register; nume's registration number is 9012878. If you want to explore whether treatment is right for you, our free consultation is the place to start, no commitment, and reviewed by a prescriber the same day you submit it.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.